Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
30.04 USD +0.23% Intraday chart for Pacira BioSciences, Inc. +3.30% -10.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy CI
Pacira BioSciences Awarded Group Purchasing Agreement with Premier MT
Pacira BioSciences Receives Brand Pharmaceuticals Agreement With Premier, Inc CI
Transcript : Pacira BioSciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus MT
Pacira Reports Unaudited Preliminary Sales Results for the Fourth Quarter and Full-Year Ended December 31, 2023 CI
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating MT
Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024 CI
Pacira Biosciences, Inc. Appoints Frank D. Lee as Member of the Board, Effective January 2, 2024 CI
Pacira BioSciences Names Frank D. Lee CEO, Board Member MT
Raymond James Initiates Pacira BioSciences With Outperform Rating, Price Target is $42 MT
Pacira BioSciences Says US FDA Approves Exparel Application for Two Additional Nerve Block Indications MT
Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications CI
HC Wainwright Adjusts Price Target on Pacira BioSciences to $57 From $63, Maintains Buy Rating MT
RBC Cuts Price Target on Pacira BioSciences to $58 From $67, Keeps Outperform Rating MT
Transcript : Pacira BioSciences, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q3 Revenue $163.9M, vs. Street Est of $172.9M MT
Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023 CI
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Barclays Adjusts Pacira BioSciences' Price Target to $57 From $60, Maintains Overweight Rating MT
Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors CI
Pacira BioSciences Chief Executive to Retire MT
Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its Chairman CI
Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO CI
Wedbush Lowers Pacira BioSciences' Price Target to $57 From $60, Keeps Outperform Rating MT
Chart Pacira BioSciences, Inc.
More charts
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain, spasticity and stellate ganglion block. The Company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.04 USD
Average target price
47.9 USD
Spread / Average Target
+59.45%
Consensus
1st Jan change Capi.
-10.97% 1 395 M $
+32.01% 693 B $
+21.62% 550 B $
+3.25% 390 B $
+18.74% 328 B $
+14.92% 315 B $
+7.97% 213 B $
-4.95% 212 B $
-3.58% 201 B $
-3.58% 157 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Pacira BioSciences, Inc. - Nasdaq
  4. News Pacira BioSciences, Inc.
  5. Pacira BioSciences Says US FDA Approves Exparel Application for Two Additional Nerve Block Indications
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer